Ronald Dagostino, DO
Cardiovascular Disease · Lake Success, NYNPI 1831134865
Payments from drug & device makers
Across 2,102 payments — averaging $387.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$194K
- Lilly USA, LLC$185K
- Johnson & Johnson$81K
- Amgen$77K
- Boston Scientific$69K
- Novo Nordisk$50K
- plus $157K from 47 others
What the payments were for
- Consulting fees$61,4438%
- Speaking & faculty fees$627,06380%
- Travel & lodging$42,9865%
- Food & beverage$50,6756%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$363,725
- XARELTO$79,431
- Repatha$71,052
- Ozempic$48,194
- Vascepa$41,902
- Barostim Neo System$34,775
- WATCHMAN Access System$34,405
- Watchman$28,935
- FLUZONE HIGH-DOSE$14,659
- BRILINTA$4,833
- DISEASE STATE$4,628
- EPANOVA$3,170
- Roszet$2,640
- WATCHMAN FLX$2,114
- Reveal LINQ$1,715
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$1,503
- LOTUS EDGE$1,500
- ATRICLIP LAA EXCLUSION SYSTEM$1,243
- CardioInsight$955
- MOUNJARO$694
How this compares
$813,903 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 678 | $835,706 |
| XareltoRivaroxaban | 440 | $493,895 |
| MounjaroTirzepatide | 185 | $230,440 |
| OzempicSemaglutide | 124 | $198,340 |
| VascepaIcosapent Ethyl | 217 | $142,615 |
| TrulicityDulaglutide | 80 | $123,551 |
| EntrestoSacubitril/Valsartan | 72 | $95,765 |
| Repatha SureclickEvolocumab | 97 | $91,463 |
| EliquisApixaban | 60 | $77,528 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $67,476 |
| Icosapent Ethyl | 159 | $56,933 |
| JanuviaSitagliptin Phosphate | 38 | $33,344 |
| VerquvoVericiguat | 35 | $32,317 |
| Eplerenone | 449 | $29,591 |
| Rosuvastatin Calcium | 1,576 | $25,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $194,480 | $835,706678 claims |
| Johnson & JohnsonXarelto | $81,177 | $493,895440 claims |
| Lilly USA, LLCMounjaro, Trulicity | $184,912 | $353,991265 claims |
| Novo NordiskOzempic, Wegovy | $50,364 | $217,983138 claims |
| NovartisEntresto | $1,995 | $95,76572 claims |
| PfizerEliquis | $1,023 | $77,52860 claims |
| AstraZenecaBreztri Aerosphere | $13,741 | $67,47669 claims |
| MerckJanuvia, Verquvo | $1,865 | $65,66173 claims |
| Esperion Therapeutics, Inc.Nexlizet | $363 | $15,13232 claims |
| AbbVieSynthroid | $335 | $5,75885 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Lake Success
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.